Zacks Investment Research Lowers SLS International (AMEX:SLS) to Sell
According to Zacks, “SELLAS Life Sciences Group is a development-stage biopharmaceutical company. It focused on novel cancer immunotherapeutics for cancer indications. The company’s product candidate, galinpepimut-S, is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 protein, which is present in an array of tumor types. SELLAS Life Sciences Group Inc., formerly known as Galena Biopharma Inc., is based in NEW YORK, United States. “
A number of other analysts also recently weighed in on the stock. Alliance Global Partners started coverage on shares of SLS International in a report on Monday, April 8th. They issued a buy rating and a $4.50 price target for the company. Maxim Group downgraded shares of SLS International from a buy rating to a hold rating in a report on Friday, March 22nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. SLS International has a consensus rating of Buy and a consensus price target of $5.55.
SLS international is a language services company which offers translations globally. The Company offers a range of services, including multilingual translations into all Spanish variants, localization, adaptation and content editing. It uses the mother-tongue linguists in order to meet the demanding standards.
Recommended Story: Terms to Better Understand Call Options
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SLS International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SLS International and related companies with MarketBeat.com's FREE daily email newsletter.